ARNOLD L ORONSKY

CIK 1207833 · last filed 2020-10-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$15.80M

Companies

12

Total Filings

55

Lifetime Open-Market Net

-$575.83M

Filer Profile

Reported Address
C/O INTERWEST PARTNERS
467 FIRST STREET SUITE 201
LOS ALTOS, CA 94022
Related Filers
PHILIP T GIANOS — 39 joint filings, latest 2017-10-17
W Stephen Holmes — 39 joint filings, latest 2017-10-17
KHALED NASR — 37 joint filings, latest 2019-11-25
Gilbert H Kliman — 33 joint filings, latest 2019-11-25
InterWest Partners IX, LP — 31 joint filings, latest 2019-11-12
BRUCE A CLEVELAND — 28 joint filings, latest 2016-03-31
InterWest Management Partners IX, LLC — 26 joint filings, latest 2019-11-12
Nina S Kjellson — 20 joint filings, latest 2015-06-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PMVP Director 6,469,911 $1.36 $8.83M $1.99M 2 2020-10-02
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director 388,766 $27.00 $10.50M $1.00M 6 2020-10-02
DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Director 37,506 $15.50 $581.3K $600.0K 18 2020-05-29
Eiger BioPharmaceuticals, Inc. (EIGR) Delisted 10%+ Owner 45,411 $1.73 $78.3K -$17.17M 1 2018-10-22
TESARO, Inc. (TSRO) Delisted Director 3,817 $10.73M 10 2018-08-09
APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Director 1,404,515 $0.39 $552.8K $0 4 2017-04-26
MGNX Director 1,708,716 $4.08 $6.96M -$7.30M 3 2014-02-18
Marketo, Inc. (MKTO) Delisted 10%+ Owner 7,663,756 -$637.37M 1 2013-09-18
Trius Therapeutics Inc (TSRX) Delisted 3,548,643 $61.37M 1 2010-08-10
MBRX Director 1,536 $0.78 $1.2K $2.32M 4 2009-06-24
ANESIVA, INC. (ANSV) Delisted Director 132,388 $8.00M 3 2008-05-12
ReShape Weightloss Inc. (ETRM) Delisted 10%+ Owner 257,794 $0 1 2007-11-21

Recent Filings · Page 5 of 6

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2011-08-04 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Other (J) −555,315 $0 EDGAR
2011-06-03 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Grant (A) $0 EDGAR
2010-08-10 Trius Therapeutics Inc (TSRX) Delisted Mixed +35,486,430 $93.98M EDGAR
2010-05-14 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Grant (A) $0 EDGAR
2009-06-24 MBRX Grant (A) $0 EDGAR
2009-06-12 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Grant (A) $0 EDGAR
2008-06-13 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Grant (A) $0 EDGAR
2008-06-11 MBRX Grant (A) $0 EDGAR
2008-05-12 ANESIVA, INC. (ANSV) Delisted Grant (A) $0 EDGAR
2008-04-18 MBRX Mixed +1,264,579 $2.96M EDGAR
Showing 4150 of 55
Page 5 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.